A Clinical Investigation of the M2a-Magnum™ Hip System
A Clinical Investigation of the M2a-Magnum™ Hip System
The purpose of this prospective clinical data collection is to document the performance and
 clinical outcomes of the M2a-Magnum™ Hip System
This is a 10 year prospective data collection documenting the function and survivorship of
 the M2a-Magnum™ Hip System. Patients are required to come in for preoperative, operative, one
 year follow-up, three year follow-up, five year follow-up, and ten year follow-up exams.

 This product was FDA cleared in 2004.
Inclusion Criteria:

 -  Non-inflammatory degenerative joint disease including: Avascular Necrosis, Diastrophic
 Variant, Fracture of the Pelvis, Fused Hip, Leg Perthes, Osteoarthritis, Slipped
 Capital Epiphysis, Subcapital Fractures, Traumatic Arthritis

 -  Rheumatoid Arthritis

 -  Correction of Functional Deformity

 -  Treatment of non-union, femoral neck fracture, and trochanteric fractures of the
 proximal femur with head involvement, unmanageable by other techniques

 -  Revision of previously failed total hip arthroplasty

 Exclusion Criteria:

 Absolute contraindications include:

 -  Infection, Sepsis, and Osteomyelitis

 Relative contraindications include:

 -  Uncooperative patient or patient with neurologic disorders that are incapable of
 following directions

 -  Osteoporosis

 -  Metabolic disorders which may impair bone formation

 -  Osteomalacia

 -  Distant foci of infections which may spread to the implant site

 -  Rapid joint destruction, marked bone loss, or bone resorption apparent on
 roentgenogram

 -  Vascular insufficiency, muscular atrophy, or neuromuscular disease